Losartan Potassium
Product Images NDC 67296-1790

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 67296-1790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan1000mg30scount (Losartan1000mg30s)

Packaging label for Losartan Potassium Tablets USP 100 mg from Camber Pharmaceuticals, Inc. The label shows the NDC 31722-702-30 and indicates a bottle containing 30 tablets. Storage instructions and warnings are included, along with manufacturer and distributor information. Barcode is visible on the right side.*

FDA Label Image

Losartan25mg90scount (Losartan25mg90s)

Label for Losartan Potassium Tablets USP 25 mg by Camber Pharmaceuticals, showing 90 tablets per container. The label includes storage instructions, a warning to keep out of reach of children, contact information, and manufacturing details by Hetero Labs Limited, India. The NDC on the label is 31722-700-90, differing from the provided NDC.*

FDA Label Image

Losartan50mg30scount (Losartan50mg30s)

Label for Losartan Potassium Tablets USP 50 mg by Camber Pharmaceuticals, containing 30 tablets. It includes dosage information, storage instructions, warnings, and contact details. The label shows the NDC 31722-701-30 and states manufacture by Camber Pharmaceuticals in Piscataway, NJ, with batch coding area and barcode.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over 60 study months between Atenolol (dotted line) and Losartan potassium (solid line). The graph shows adjusted risk reduction of 13% with Losartan potassium, with p=0.021, indicating a lower percentage of patients reaching the endpoint over time compared to Atenolol.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over months of study for two treatments: Losartan Potassium and Atenolol. The graph shows study months on the x-axis and percentage of patients on the y-axis, illustrating a lower stroke incidence with Losartan Potassium. Additional text notes an adjusted risk reduction of 25% with statistical significance (p=0.001).*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot titled 'Primary Endpoint Events within Demographic Subgroups' comparing losartan potassium and atenolol event rates for primary composite and stroke (fatal/non-fatal) outcomes. The chart lists patient subgroups by age, gender, race, ISH, diabetes, and history of cardiovascular disease, showing event rates (%) and hazard ratios with 95% confidence intervals for each subgroup, visually indicating which treatment is favored.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line chart comparing the percentage of patients with events over 48 months for Losartan potassium versus placebo. The graph shows risk reduction data with Losartan potassium, indicating a significant difference (p=0.022). The x-axis represents time in months, and the y-axis shows the percentage of patients with events.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of the active ingredient Losartan Potassium, showing its molecular configuration including potassium ion (K+), chlorine atom, and multiple aromatic rings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.